Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Stanford University Medical Center School of Medicine
mi
from
Stanford, CA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Stanford University Medical Center School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Medical Specialist of Palm Beaches
mi
from
Lake Worth, FL
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Medical Specialist of Palm Beaches
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch
mi
from
Miami Shores, FL
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch
mi
from
Miami Shores, FL
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Emory University School of Medicine/Winship Cancer Institute
mi
from
Atlanta, GA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Emory University School of Medicine/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
NorthWest Georgia Oncology Centers NW Georgia Oncology Centers PC
mi
from
Marietta, GA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
NorthWest Georgia Oncology Centers NW Georgia Oncology Centers PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Quincy Medical Group
mi
from
Quincy, IL
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Quincy Medical Group
mi
from
Quincy, IL
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
mi
from
New Orleans, LA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
St. Agnes Hospital Healthcare Cancer Center
mi
from
Baltimore, MD
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
St. Agnes Hospital Healthcare Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Newland Medical Associates, PC Newland Medical - Southfield
mi
from
Southfield, MI
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Newland Medical Associates, PC Newland Medical - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Hubert H. Humphrey Cancer Center - Coon Rapids
mi
from
Edina, MN
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Hubert H. Humphrey Cancer Center - Coon Rapids
mi
from
Edina, MN
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hematology,
mi
from
Minneapolis, MN
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Minnesota Oncology Hematology, P.A. Minnesota Oncology Hematology,
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Missouri Cancer Associates Dept.ofMissouriCancerAssoc.
mi
from
Columbia, MO
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Missouri Cancer Associates Dept.ofMissouriCancerAssoc.
mi
from
Columbia, MO
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
East Orange VA Medical Center SC
mi
from
East Orange, NJ
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
East Orange VA Medical Center SC
mi
from
East Orange, NJ
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Legacy Pharma Research
mi
from
Bismarck, ND
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Legacy Pharma Research
mi
from
Bismarck, ND
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Dayton CCOP
mi
from
Dayton, OH
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Dayton CCOP
mi
from
Dayton, OH
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Western Pennsylvania Cancer Institute /Western Penn Hospital Western Pann. Cancer Inst.
mi
from
Pittsburgh, PA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Western Pennsylvania Cancer Institute /Western Penn Hospital Western Pann. Cancer Inst.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Pharma Resource
mi
from
East Providence, RI
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Vanderbilt Univeristy SC
mi
from
Nashville, TN
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Vanderbilt Univeristy SC
mi
from
Nashville, TN
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Cancer Center of the High Plains
mi
from
Amarillo, TX
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Cancer Center of the High Plains
mi
from
Amarillo, TX
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
MD Anderson Cancer Center/University of Texas MD Anderson CC
mi
from
Houston, TX
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
MD Anderson Cancer Center/University of Texas MD Anderson CC
mi
from
Houston, TX
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Columbia Basin Hematology SC
mi
from
Kennewick, WA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Columbia Basin Hematology SC
mi
from
Kennewick, WA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Swedish Cancer Institute SC
mi
from
Seattle, WA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Swedish Cancer Institute SC
mi
from
Seattle, WA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
West Virginia University/Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
West Virginia University/Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Kaiser Permanente - California Southern Kaiser Permanente SCPMG
mi
from
San Diego, CA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Kaiser Permanente - California Southern Kaiser Permanente SCPMG
mi
from
San Diego, CA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Kaiser Permanente Onc Dept
mi
from
San Diego, CA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Kaiser Permanente Onc Dept
mi
from
San Diego, CA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Kaiser Permanente
mi
from
San Diego, CA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Boca Raton Community Hospital SC
mi
from
Boca Raton, FL
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Boca Raton Community Hospital SC
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
University Cancer and Blood Center LLC
mi
from
Athens, GA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Loyola University Medical Center
mi
from
Marywood, IL
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Loyola University Medical Center
mi
from
Marywood, IL
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Associates in Oncology and Hematology
mi
from
Rockville, MD
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Mount Kisco Medical Group
mi
from
Mt. Kisco, NY
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Mount Kisco Medical Group
mi
from
Mt. Kisco, NY
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
St Mary Medical Center
mi
from
Walla Walla, WA
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
St Mary Medical Center
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated:  9/21/2015
Novartis Investigative Site
mi
from
La Plata,
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
Status: Enrolling
Updated: 9/21/2015
Novartis Investigative Site
mi
from
La Plata,
Click here to add this to my saved trials
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  9/22/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 9/22/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated:  9/22/2015
Johns Hopkins University
mi
from
Baltimore, MD
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated: 9/22/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated:  9/22/2015
NY Presbyterian-Cornell
mi
from
New York City, NY
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated: 9/22/2015
NY Presbyterian-Cornell
mi
from
New York City, NY
Click here to add this to my saved trials
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated:  9/22/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated: 9/22/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated:  9/22/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status: Enrolling
Updated: 9/22/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated:  9/23/2015
Texas Children's Hospital
mi
from
Houston, TX
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated: 9/23/2015
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated:  9/23/2015
Methodist Hospital
mi
from
Houston, TX
Stem Cell Transplant for Hematologic Diseases
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H
Status: Enrolling
Updated: 9/23/2015
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
Barrow Neurosurgical Associates
mi
from
Phoenix, AZ
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
Barrow Neurosurgical Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
Silicon Valley Spine Institute
mi
from
Campbell, CA
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
Silicon Valley Spine Institute
mi
from
Campbell, CA
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
Hoag Memorial Hospital
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated:  9/23/2015
Bay Area Spine Institute
mi
from
Walnut Creek, CA
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF
Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease
Status: Enrolling
Updated: 9/23/2015
Bay Area Spine Institute
mi
from
Walnut Creek, CA
Click here to add this to my saved trials